Status:
COMPLETED
Impact of the Central Blood Pressure Level in Cerebral Metabolic Aging: a 18F-FDG PET Study.
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Aging Disorder
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Cerebral glycolytic metabolism can be quantified by quantitative analysis of 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography (PET). This allows to identify neurological diseases at an ea...
Eligibility Criteria
Inclusion
- \> 18 years old, with written informed consent,
- Subjects referred for 18F-FDG PET in a non-oncological setting,
- Absence of pregnancy or breastfeeding,
- Lack of chemotherapy in the previous year and no cerebral radiotherapy.
- No history of psychiatric or neurological pathology.
- Absence of treatment with psychotropic action, and absence of corticosteroids.
Exclusion
- "abnormal" neuropsychological tests:
- Mini Mental State Examination (MMSE) \<27,
- Current major depressive episode on the Mini International Neuropsychologic Interview (MINI),
- Frontal Assessment Battery (FAB) \<15.
- 18F-FDG PET examination showing ischemic, neurodegenerative, neoplastic or other brain lesions (independent of a normal or accelerated aging process).
Key Trial Info
Start Date :
July 31 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 6 2020
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT03345290
Start Date
July 31 2018
End Date
November 6 2020
Last Update
August 24 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU Nancy
Vandœuvre-lès-Nancy, France, 54511